September 10, 2018
Genetic Signatures’ CEO Dr. John Melki interview by Proactive Investors
Genetic Signatures’ CEO Dr. John Melki was recently interviewed by Proactive investors at the ASX Small and Mid-Cap Conference.
See the link below to learn more about our 3baseTM technology and EasyScreenTM assays, and how we’re improving patient outcomes.
For more information click the link: Genetic Signatures’ clinical trials demonstrate product efficacy.
September 7, 2018
Genetic Signatures article from The Australian Financial Review.
Genetic Signatures featured in The Australian Financial Review.
For more information click the link: Winning the war on superbugs
September 5, 2018
Genetic Signatures’ CEO Dr. John Melki presenting at the inaugural ASX Small and Mid-Cap Conference 6th September, Sydney, Australia.
Join ASX for the inaugural ASX Small and Mid-Cap Conference, showcasing emerging leaders in the small and mid-cap category. This is a unique opportunity to hear from a broad range of ASX-listed companies and their CEOs in the comfortable surrounds of the International Convention Centre at Darling Harbour.
This conference aims to welcome over 400 attendees from the finance industry, with an emphasis on SMSF / sophisticated investors.
Visit John and the team to learn more about the directions of Genetic Signatures.
For more information regarding the conference click here, and the presentation may be viewed here
